Salta al contenuto principale

Dott. Mauro Porpiglia – Ginecologo e Senologo a Torino

images

Didattica e Ricerca

Integrazione tra attività scientifica e pratica clinica quotidiana

Attività Didattica

Attività scientifica e di ricerca

Autore di oltre 50 pubblicazioni su riviste internazionali, relatore e moderatore in congressi nazionali, collabora con importanti società scientifiche ed è sperimentatore principale in numerosi studi clinici focalizzati al trattamento del tumore della mammella

Dott Mauro Porpiglia - Congresso Tumore Mammella - ostetricia ginecologia
  • Icon TUTOR al Corso di Laurea in Medicina e Chirurgia, Università degli Studi di Torino
  • Icon 2012-2013 PROFESSORE A CONTRATTO in Ginecologia e Ostetricia al Corso di Laurea in Infermieristica Università di Torino
  • Icon Dal 2017 DOCENTE al Master Universitario di II livello in “Senologia multidisciplinare” Università di Torino
  • Icon Dal 2017 al 2023 DOCENTE al corso “PFP Breast Unit – C.O.R.E. (Chirurgia Oncologica Ricostruttiva ed Estetica) presso A.O.U. Città della Salute e della Scienza di Torino
  • Icon 2021-2022 DOCENTE in Ginecologia ed Ostetricia alla Scuola di Specializzazione in Urologia, Università di Torino
  • Icon 2024 DOCENTE Master II livello Farmacia Territoriale “Chiara Colombo” Università di Torino

Attività Scientifica e di Ricerca

Autore di oltre 50 pubblicazioni su riviste internazionali, relatore e moderatore in congressi nazionali, collabora con importanti società scientifiche ed è sperimentatore principale in numerosi studi clinici focalizzati sul trattamento del tumore della mammella

Attività Scientifica

  • COMPONENTE del Gruppo Interdisciplinare Cure (GIC) “Tumori della mammella” A.O.U. Città della Salute e della Scienza di Torino;
  • COMPONENTE Gruppo di studio “Tumore della Mammella” Rete Oncologica Piemonte e Valle d’Aosta
  • ESTENSORE PDTA “Tumori della Mammella” e PDTA “Gestione della persona assistita a rischio ereditario di tumore della mammella e/o dell’ovaio”, presso la A.O.U. Città della Salute e della Scienza di Torino;
  • COMITATO SCIENTIFICO della “Associazione Nazionale Donne Operate al Seno” (ANDOS);
  • MEMBRO della società scientifica di chirurgia senologica “European Breast Cancer Reserch Association of Surgical Trialists” (EUBREAST);

Pubblicazioni scientifiche PubMed

  1. “Perinatal mortality in placental insufficiency”. Minerva Ginecol Dec;41(12): 589-91;
  2. “The inflammations of the uterine corpus: endometritis”. Minerva Ginecol 1990, 42 (4): 99-102;
  3. “Urinary tract infections during pregnancy”. Minerva Ginecol. 1990 Jun 42(6): 263-5;
  4. “Pathologic conditions related to sterilization in the female”. Minerva Ginecol 1990 Oct; 42(10): 403-4;
  5. “La sindrome feto-alcolica”. Gazz. Med. It., Vol.151, N.3 (Marzo 1992);
  6. “Ovarian hyperstimulation syndrome (OHS): borderlines between physiology ad pathology” Minerva Ginecol 1994 Jul-Aug; 46(7-8): 413-6;
  7. “Obesity: internal medicine, obstetric and ginecological problems related to overwight”. Med., Vol.36, N.3 (September 1994);
  8. “Efficacy of Fat Mobilisation System (FMS) in the treatment of obesity and its utility in the resolution of gynecological problems related to overweight”. Med., Vol.36, N.3 (September 1994);
  9. “Intramuscolar beta-interferon in the treatment of cervical intraepithelial neoplasia (CIN) associated with human papilloma virus (HPV) infection”. Minerva Ginecol 1994 Oct; 46(10): 579-82;
  10. “Asymptomatic bacteriuria in pregnancy: maternal and fetal complications”. Med., Vol.36, N.4 (December 1994);
  11. “Asymptomatic bacteriuria in pregnancy: a diagnostic and terapeutic approach”. Med., Vol.36, N.4 (December, 1994);
  12. “Dysspermia due to inflammation. The evaluation of sperm cultures”. Minerva Ginecol 1995, Jul-Aug; 47 (7-8): 327-9;
  13. “Use of a GnRH analogue (leuprorelin) in the therapy of endometriosis””. Minerva Ginecol 1997 Sep;49(9): 417-9;
  14. “Clinical efficacy of tamoxifen in the treatment of premenstrual mastidynia” Minerva Ginecol 1998 Mar;50(3): 101-3;
  15. “Menopause. Hormone substitution therapy and prevention of cardiovascolar risk”. Minerva Ginecol 1998 Jul-Aug;50(7-8):329-31;
  16. “Anomalous uterine hemorrhage in climateric. Their etiopathogenesis”. Minerva Ginecol 1998 Sep;50(9): 383-8;
  17. “Abnormal uterine hemorrhage in climateric. Diagnostic approach”. Minerva Ginecol 1998 Oct; 50(10): 429-33;
  18. “Abnormal uterine hemorrhage in climateric. Medical management”. Minerva Ginecol 1998 Nov; 50(11): 475-6;
  19. “Sexuality in menopause: Importance of adequate replacement therapy” Minerva Ginecol 1999 Mar;51(3):59-62;
  20. “Abnormal uterine bleeding during climateric. Correlation between transvaginal ultrasonography, hysteroscopy and histology” Minerva Ginecol 1999 Apr;51(4):125-7;
  21. “The role of aromatase inhibitors in the treatment of breast neoplasms. An evaluation of clinical efficacy and the tolerability profile”. Minerva Ginecol 2002 Apr;54(2):115-131;
  22. “Oral squamous carcinoma in patient with cervix cancer: use of human papillomavirus analysis to differentiate synchronous versus metastatic tumor”. Gynecologic Oncology 89 (2003) 522-525;
  23. “Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment”. Breast Cancer Res Treat 82: Suppl 1, 2003;
  24. “Biologic therapy and epithelial ovarian cancer” Minerva Ginecol 2004 Feb;56(1):91-104;
  25. “Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial”. J Clin Oncol 23: 1-10, 2005;
  26. “Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial”. Ann Oncol 2006 Jun; 17 Suppl 7: vii 10-4;
  27. “Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: pooled analysis of 2 consecutive trials”. Cancer 2007 Mar 15; 109 (6): 1060-7;
  28. “Adjuvant treatment of early breast cancer: do the St Gallen recommendations influence clinical practice? Results from the NORA study” Ann Oncol 18: 1976-1980, 2007 (collaboratore);
  29. “A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy”. Clin Cancer Res 2007 Dec 1; 13 (23): 6984-92;
  30. “Is sialys lewis x antigen expression a prognostic factor in patients with breast cancer?”. Int J Surg pathol 2008 Oct: 16 84) 365-74;
  31. “Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study”, Lancet Oncol. 2012 Apr;13(4):420-32 (collaboratore);
  32. “Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole” Breast Cancer Res Treat. 2012 Nov 6;
  33. “Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: long term results of the Italian Tamoxifen anastrozole Trial” Eur J Cancer 2013 May; 49(7): 1546-54;
  34. “Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial” Lancet 2014 Mar 22; 383(9922):1041-8 (collaboratore);
  35. “Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole” Br J Cancer. 2014 Mar 4;110(5):1133-8;
  36. “Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial” Lancet. 2016 Feb 27; 387(10021):866-73 (collaboratore);
  37. “Pregnancy-associated breast cancer: tumor features and obstetrical outcomes in a single institution retrospective study”, Obstetrics & Gynecology International Journal 2017, 7 (1);
  38. “Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study” Breast. 2017 Oct; 35:115-121;
  39. “Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study” Ann Onc 2018 Dec 1;29(12):2328-2333 (collaboratore);
  40. “Axillary dissection vs. no axillary dissection in breast cancer patients with positive institution experience”, In vivo 2019 Nov-Dec; 33 (6): 1941-1947;
  41. “Is there a Role for Endocrine Therapy alone in HR+/HER2- advanced breast cancer patients? Results from the analysis of two data sets of patients treated with high-dose fulvestrant as first-line therapy in the real-world setting: the EVA and GIM-13 AMBRA studies”, Breast Care 2020 Feb; 15(1): 30-37;
  42. “Carbon tattooing of axillary lymph nodes in breast cancer patients before neoadjuvant chemotherapy: A retrospective analysis.” 2023 Jun;109(3):301-306″
  43. “Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial”. JAMA Oncol. 2023 Nov 1;9(11):1557-1564;
  44. “SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials.” Clin Cancer Res. 2023 Dec 15;29(24):5217-5226;
  45. “Targeted axillary dissection: worldwide variations in clinical practise” Breast Cancer Res Treat 2024 Apr (collaboratore);
  46. “Borderline Phyllodes Breast Tumors: A Comprehensive Review of Recurrence, Histopathological Characteristics, and Treatment Modalities.” Curr Oncol. 2025 Jan 26;32(2):66;
  47. “Lost axillary markers after neoadjuvant chemotherapy in breast cancer patients – data from the prospective international AXSANA (EUBREAST 3) cohort study (NCT04373655).” Eur J Surg Oncol. 2025 Jun 25;51(9);
  48. “Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients – Results from the prospective AXSANA registry trial.” Eur J Cancer. 2025 Aug 26;226:
  49. “Axillay dissection in low-volume nodal involvement after neoadjuvant therapy in breast cancer: multicentre AXSANA Cohort study” British Journal of Cancer Sep 2, 112(9);
  50. “Marking techniques for target lymph nodes among 2.596 node-positive breast cancer patients treated with neoadjuvant therapy in the AXSANA/EUBREAST-03/AGO-B-053 study“, Journal of Clinical Oncology, 2026 Jan 21

Attività di Ricerca

Collaboratore

  • Collabora con alcune delle più autorevoli società scientifiche nazionali (Gruppo Italiano Mammella “GIM”) ed internazionali (European Breast Cancer Research Association of Surgical Trialists “EUBREAST”), e Breast Unit nazionali (Istituto Europeo di Oncologia di Milano, Istituto San Raffaele di Milano), per la conduzione di trials clinici focalizzati sul trattamento del tumore della mammella

Principal / Co-Investigator Studi Clinici

  1. Studio IES: “Randomised double-blind trial in postmenopausal women with primary breast cancer who have received adjuvant tamoxifen for 2-3 years, comparing subsequent adjuvant exemestane treatment with further tamoxifen”;
  2. Studio ITA 1033IT/0002: “Studio clinico randomizzato in aperto di terapia adiuvante nelle donne in post-menopausa con cancro della mammella: Tamoxifen o Tamoxifen seguito da Arimidex”;
  3. Studio NORA: “Studio osservazionale sulle modalità di trattamento adiuvante e sui pattern di ricaduta delle pazienti con carcinoma mammario operato”;
  4. Studio IBIS II: “Trial di farmacoprevenzione e trattamento del CDIS in donne in postmenopausa”;
  5. Studio “Role of the CYP19 ex11+410G>T and other genetic polymorphisms on response to exemestane as first line treatment in patients with metastatic breast carcinoma”;
  6. Studio GIM5- CYPLEC. “Letrozole adjuvant therapy after tamoxifen: study of gene CYP19 and correlation with disease free survival and overall survival in early breast cancer postmenopausal patients”;
  7. Studio ShortHER: “Trattamento adiuvante con Herceptin per 3 mesi verso 12 mesi, in associazione con 2 differenti regimi di chemioterapia, nelle pazienti con carcinoma mammario HER2 positive”;
  8. Studio DOUBLE: “Open label, phase III, multicentric randomised trial, comparing 3-2 years of treatment with either anastrozole (ANA) or letrozole (LTZ), versus switching to exemestane (EXE) after 2-3 years of treatment with either of the previous two in early stage postmenopausal breast cancer patients”;
  9. Studio BELLE-3: “A phase III randomized, double blind, placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative AI treated, locally advanced or metastatic breast cancer who progressed on or after mTOR inhibitor based treatment”;
  10. Studio SOUND: “Studio randomizzato di confronto tra biopsia del linfonodo sentinella e nessuna biopsia chirurgica ascellare in pazienti con carcinoma mammario iniziale e diagnostica pre-operatoria del cavo ascellare negativa”;
  11. Studio AXSANA: “A prospective multicenter cohort study to evaluate different surgical methods of axillary staging (sentinel lymph node biopsy, targeted axillary dissection, axillary dissection) in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy”;
  12. Studio “Impatto della restrizione calorica e dell’attività fisica adattata in pazienti con cancro della mammella in fase pre-operatoria”;
  13. Studio EUBREAST 01: “Omission of sentinel lymph node biopsy in triple-negative and HER2- positive breast cancer patients with radiologic and pathologic complete response in the breast after neoadjuvant systemic therapy: a single-arm, prospective surgical trial”;
  14. Studio I-PREPARE EUBREAST-11R: “International Prospective Registry on Pre-pectorAl breast Reconstruction”

 

  • Studio Medico Ginecologico
  • Corso Re Umberto 147, Torino
Unisciti alle tante donne che hanno scelto un percorso di prevenzione e cura con attenzione, ascolto e competenza.
Arrow icon Prenota una visita Arrow icon